Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

In a Phase 3 test that compared Enflonsia to Synagis, the safety of the Merck drug was comparable to the AstraZeneca product. Pfizer’s presence in RSV is through Abrysvo, a vaccine comprised of ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck said. The United States already has multiple tools to prevent severe RSV in infants, including Sanofi’s monoclonal antibody (mAb), nirsevimab, and a maternal vaccine from Pfizer.

This week, The FDA accepted Merck & Co.’s biologics license application for the monoclonal antibody clesrovimab, which works differently from a vaccine but also provides protection against RSV.